003060.KS
Aprogen Biologics Inc.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 1,727.00
−0.86%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 86.2B | 73.2B | 67.4B | 87.4B | 65.2B |
| Cost of Revenue | 110.3B | 101.6B | 75.0B | 99.4B | 37.9B |
| Gross Profit | (23.3B) | (28.4B) | (7.6B) | (12.0B) | 27.3B |
| Operating Expenses | |||||
| R&D Expense | 3.2B | 3.0B | 18.0B | 15.0B | 2.2B |
| SG&A Expense | 17.2B | 17.2B | 16.7B | 18.6B | 17.8B |
| General & Admin Expense | 1.9B | 2.7B | 2.5B | 3.1B | 3.3B |
| Selling & Marketing Expense | 12.0B | 14.4B | 14.3B | 15.5B | 14.6B |
| Other Expenses | 65.5B | 74.3B | 10.5B | 12.6B | 13.0B |
| Total Operating Expenses | 85.9B | 94.5B | 45.2B | 58.6B | 33.0B |
| Cost and Expenses | 204.8B | 196.1B | 120.2B | 158.1B | 70.9B |
| Operating Income (EBIT) | (118.7B) | (122.9B) | (52.8B) | (70.0B) | 12.8B |
| Non-Operating | |||||
| Interest Income | 11.9B | 9.9B | 4.2B | 4.5B | 16.6B |
| Interest Expense | 14.8B | 10.7B | 5.5B | 3.7B | 274.4M |
| Net Interest Income | (2.9B) | (824.4M) | (1.3B) | 820.0M | 16.4B |
| Other Non-Op Income/Expense | 45.0B | (46.5B) | (52.2B) | (43.4B) | 20.3B |
| Non-Operating Income (excl Interest) | 26.8B | — | 11.8B | 39.8B | (20.6B) |
| EBT (Pre-Tax Income) | (73.6B) | (169.4B) | (105.0B) | (113.4B) | 6.8B |
| Income Tax Expense | (1.1B) | (1.1B) | (29.0B) | 1.9B | 1.3B |
| Bottom Line | |||||
| Net Income | (78.3B) | (170.3B) | (105.0B) | (118.3B) | 5.6B |
| Earnings from Cont. Ops | (72.6B) | (168.3B) | (105.0B) | (115.3B) | 12.3B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (78.3B) | (170.3B) | (105.0B) | (118.3B) | 12.6B |
| Per Share | |||||
| Basic EPS | (₩5,875) | (₩12,924) | (₩12,519) | (₩21,306) | ₩1,560 |
| Diluted EPS | (₩5,875) | (₩12,931) | (₩12,519) | (₩21,306) | ₩1,560 |
| Revenue Per Share | ₩6,161 | ₩5,533 | ₩8,031 | ₩15,738 | ₩18,217 |
| Shares | |||||
| Basic Shares Outstanding | 14.0M | 13.2M | 8.4M | 5.6M | 3.6M |
| Diluted Shares Outstanding | 14.0M | 13.2M | 8.4M | 5.6M | 3.6M |
| Profitability Metrics | |||||
| EBITDA | (27.7B) | (103.7B) | (51.3B) | (88.3B) | 16.0B |
| D&A | 19.4B | 19.2B | 19.1B | 21.4B | 2.2B |
| EBIT | (121.5B) | (122.9B) | (70.4B) | (109.7B) | 15.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026